US Patent

US9796712 — Heteroaryl compounds for kinase inhibition

Composition of Matter · Assigned to Ariad Pharmaceuticals Inc · Expires 2035-05-13 · 9y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and their pharmaceutical compositions.

USPTO Abstract

Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.

Drugs covered by this patent

Patent Metadata

Patent number
US9796712
Jurisdiction
US
Classification
Composition of Matter
Expires
2035-05-13
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Ariad Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.